Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights.
Study Design
- Çalışma Türü
- Randomized Controlled Trial
- Popülasyon
- IBS patients
- Süre
- 3 weeks
- Müdahale
- Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. None
- Karşılaştırıcı
- Placebo
- Birincil Sonuç
- Pain outcomes
- Etki Yönü
- Positive
- Yanlılık Riski
- Low
Abstract
Different nutraceuticals are often considered by parents of infants and children with abdominal pain and disorders of the gut-brain interaction. Herb extracts and natural compounds have long been used in traditional medicine, but clinical pediatric trials are very limited. This narrative review based on relevant studies identified through a search of the literature in Pubmed and Medline updated to October 2023 focused on the effect of nutraceuticals in infantile colic, functional abdominal pain, and irritable bowel syndrome in children and adolescents. Significant reductions in colic episodes and crying time were reported in two studies on fennel (seeds oil or tea), in three studies on different multiple herbal extracts (all including fennel), in one study on Mentha piperita, and in at least two double-blind randomized controlled studies on Lactobacillus reuteri DSM 17938 and Bifidobacterium lactis BB-12 (108 CFU/day for at least 21 days) in breast-fed infants. Compared to a placebo, in children with functional abdominal pain or irritable bowel syndrome, a significant reduction in pain was reported in two studies supplementing peppermint oil capsules or psyllium fibers, and in one study on corn fiber cookies, partial hydrolyzed guar gum, a specific multiple herbal extract (STW-5), or vitamin D supplementation. To date, there is moderate-certainty evidence with a weak grade of recommendation on Lactobacillus reuteri DSM 17938 (108 CFU/day) in reducing pain intensity in children with functional abdominal pain and for Lactobacillus rhamnosus GG (1-3 × 109 CFU twice daily) in reducing pain frequency and intensity in children with IBS. Further large and well-designed pediatric studies are needed to prove the efficacy and safety of different herbal extracts and prolonged use of studied products in infants and children with pain disorders of the gut-brain interaction.
Kısaca
There is moderate-certainty evidence with a weak grade of recommendation on Lactobacillus reuteri DSM 17938 in reducing pain intensity in children with functional abdominal pain and for Lactobacillus rhamnosus GG in reducing pain frequency and intensity in children with IBS.
Full Text
Used In Evidence Reviews
Similar Papers
The American journal of gastroenterology · 2006
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease.
Phytotherapy research : PTR · 2006
A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.).
The American journal of clinical nutrition · 2001
Protection from gastrointestinal diseases with the use of probiotics.
The Journal of pediatrics · 1999
Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children.
BMJ (Clinical research ed.) · 2008
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
Advances in biochemical engineering/biotechnology · 2008